Search

Table S1: Genes significantly differentially expressed in samples with pathological complete response compared to those without in the Combination arm. Table S2: DAVID analysis of 720 differentially expressed genes in tumors that achieved pathological complete reponse compared to those that did not, in the combination arm. Table S3 : Genes significantly differentially expressed in samples with pathological complete response compared to those without in the Chemotherapy arm. Table S4: DAVID analysis of 1243 differentially expressed genes in tumors that achieved pathological complete reponse compared to those that did not, in the chemotherapy arm. Table S5 : List of genes with significant lower expression in week 12 samples treated with combination therapy compared to those treated with chemotherapy Table S6: DAVID analysis of 42 differentially expressed genes in week-12 tumors in the combination arm compared to chemotherapy arm. Table S7 : Differentially expressed genes between week-0 and week-12 in Basal-like tumors treated with combination therapy Table S8 : Differentially expressed genes between week-0 and week-12 Luminal B tumors treated with combination therapy Table S9 : Differentially expressed genes between week-0 and week-12 Luminal A tumors treated with combination therapy Table S10: Differentially expressed genes between week-0 and week-12 Basal-like tumors treated with chemotherapy Table S11 : Differentially expressed genes between week-0 and week-12 Luminal B tumors treated with chemotherapy Table S12 : Differentially expressed genes between week-0 and week-12 Luminal A tumors treated with chemotherapy Table S13: Pathways significantly altered between Chemotherapy and Combination therapy arms from week-0 to week-12 LuminalB samples Table S14: Pathways significantly altered between anthracycline and taxane treatment in the Luminal A samples in chemotherapy arm

Purpose: Chemotherapy-induced alterations to gene expression are due to transcriptional reprogramming of tumor cells or subclonal adaptations to treatment. The effect on whole-transcriptome mRNA expression was investigated in a randomized phase II clinical trial to assess the effect of neoadjuvant chemotherapy with the addition of bevacizumab.Experimental Design: Tumor biopsies and whole-transcriptome mRNA profiles were obtained at three fixed time points with 66 patients in each arm. Altogether, 358 specimens from 132 patients were available, representing the transcriptional state before treatment start, at 12 weeks and after treatment (25 weeks). Pathologic complete response (pCR) in breast and axillary nodes was the primary endpoint.Results: pCR was observed in 15 patients (23%) receiving bevacizumab and chemotherapy and 8 patients (12%) receiving only chemotherapy. In the estrogen receptor–positive patients, 11 of 54 (20%) treated with bevacizumab and chemotherapy achieved pCR, while only 3 of 57 (5%) treated with chemotherapy reached pCR. In patients with estrogen receptor–positive tumors treated with combination therapy, an elevated immune activity was associated with good response. Proliferation was reduced after treatment in both treatment arms and most pronounced in the combination therapy arm, where the reduction in proliferation accelerated during treatment. Transcriptional alterations during therapy were subtype specific, and the effect of adding bevacizumab was most evident for luminal-B tumors.Conclusions: Clinical response and gene expression response differed between patients receiving combination therapy and chemotherapy alone. The results may guide identification of patients likely to benefit from antiangiogenic therapy. Clin Cancer Res; 23(16); 4662–70. ©2017 AACR.

Supplementary figures as referred to in the manuscript

I denne artikkelen evaluerer vi hvordan strengere klimapolitikk påvirker norske lån til utlandet. Ved å benytte syndikerte lånedata fra Norge og klimaindeksen fra Germanwatch for både Norge og mottakerlandene i perioden 2007 til 2017, finner vi to stiliserte resultater. Først avdekker vår analyse på aggregatnivå at en strengere innenlands klimapolitikk i Norge fører til en reduksjon i andelen lån som norske banker utsteder til utenlandske låntakere. For det andre indikerer våre resultater at strengere klimapolitikk i mottakerlandet ikke påvirker størrelsen på utenlandslån fra norske banker. Samlet sett peker våre resultater på mangel på bevis for regulatorisk arbitrasje i det norske markedet for syndikerte lån. In this paper, we study how climate policy stringency affects cross-border lending in Norway. Using syndicated loan data from Norway and Climate Change Performance Index for both Norway and recipient countries from 2007 to 2017, we find two stylized results. First, our aggregate-level analysis reveal that a more stringent domestic climate policy in Norway tends to reduce the proportion of loans that Norwegian banks extend to foreign borrowers. Second, when looking at cross-country evidence, our results indicate that Norwegian banks cross-border lending amount does not seem to respond to changes in international climate policy regulation stringency. Altogether, our results point to no evidence of regulatory arbitrage in the Norwegian syndicated loan market.